One of the keys to successful investing is holding shares of companies that can perform well over long periods. However, few companies can thrive for that long while delivering excellent returns to investors. Those that do tend to have some key attributes, including a strong moat and attractive growth opportunities.Looking for stocks that fit this description? Let's consider two great examples: Eli Lilly (LLY -6.55%) and Veeva Systems (VEEV -3.52%). Here's what investors need to know about these market lead ...

Group 1 - Sangamo Therapeutics, Inc. (NASDAQ: SGMO) has established a deal with Eli Lilly and Company (LLY) to advance up to 5 neurological programs [2] - The article is authored by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace, providing in-depth analysis of pharmaceutical companies [1][2] - The Biotech Analysis Central service includes a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [2]

Eli Lilly (LLY -2.70%) is the most valuable healthcare company in the world, worth more than $700 billion. Over the past 12 months, however, the stock's performance has been fairly lackluster, rising by just around 6%. Investors are beginning to scoff at its expensive price tag, with Eli Lilly trading at more than 70 times its trailing earnings.But there could be a big catalyst ahead in April, which may trigger a broad rally for the stock.Eli Lilly may soon release data on its weight loss pillA key drug tha ...

Call the lobbyists! The market might have been better able to swallow the looming tariffs if there weren't so much uncertainty about them. As of late afternoon Tuesday, it was still unclear how much the U.S. would levy foreign manufacturers of medicines. While speculation has been rife and the president has said these would be 25%, a giant question mark was hanging over the matter. Naturally, some of the most determined pharma industry lobbyists were campaigning for at least a ramp-up to those 25% charges. ...

In the paper, Kanvas demonstrates that its technology outperforms conventional sequencing, achieving a sensitivity of 0.01% and enabling species-level microbial identification. PRINCETON, N.J., April 1, 2025 /PRNewswire/ -- Kanvas Biosciences, a full-stack spatial biology company, today announced new research outlining the capabilities of its High-Phylogenetic-Resolution Spatial Mapping (HiPR-Map) Platform, a state-of-the-art spectral imaging technology that enables precise enumeration and spatial localizat ...

The Eli Lilly logo is shown on one of the company's offices in San Diego, California, on Sept. 17, 2020. Eli Lilly is suing two pharmacies for compounding Zepbound and Mounjaro, claiming the companies are skirting the Food and Drug Administration's ban on the practice and luring people away from Lilly's medicines. In lawsuits filed Tuesday in Delaware and New Jersey, Lilly alleges the two companies — Strive Pharmacy and Empower Pharmacy — are falsely marketing their products as personalized versions of the ...

Eli Lilly's potential game changer in the GLP-1 agonist market The market for GLP-1 agonists is red-hot. Some experts believe annual sales of the popular drugs will grow to $150 billion by 2030 -- these weight loss drugs work by slowing digestion in the body and suppressing appetite. GLP-1 agonists are primarily approved and used to treat type 2 diabetes and chronic obesity. In addition, some patients are taking them to treat sleep apnea and reduce the risk of cardiovascular disease. Today, Novo Nordisk and ...

Group 1 - Direxion has launched four single-stock leveraged and inverse ETFs focused on Eli Lilly & Co and Palo Alto Networks Inc, providing traders with tools to amplify their investments or hedge against market downturns in the pharmaceutical and cybersecurity sectors [1][2] - Eli Lilly is recognized for its leadership in healthcare innovation, while Palo Alto Networks is a leader in cybersecurity, making them suitable candidates for leveraged trading [2] - Recent performance shows Eli Lilly has increased by 9.99% over the past year but decreased by 6.85% in the last month, whereas Palo Alto Networks has risen by 32.51% year-over-year with a slight gain of 0.21% in the past month [3] Group 2 - The newly introduced ETFs are designed for short-term trading strategies and are not suitable for buy-and-hold investors due to their high volatility and risk [4] - These leveraged and inverse funds track individual stocks rather than indices, which contributes to their increased risk profile [4] - For high-risk tolerant traders, Direxion's ETFs present an opportunity to engage with fast-moving stocks using leverage [4]

Core Viewpoint - Investing in stocks remains a strong long-term strategy despite current market volatility, with Eli Lilly and Shopify highlighted as two compelling investment opportunities [1] Group 1: Eli Lilly - Eli Lilly is a leading pharmaceutical company focused on therapies for severe illnesses, including diabetes and weight management, which are in high demand [2] - In 2024, Eli Lilly's revenue increased by 32% year-over-year to approximately $45 billion, with guidance for 2025 suggesting continued growth at a similar rate [3] - The company's promising pipeline includes diabetes drugs, anti-obesity medicines, and innovative treatments for conditions like Alzheimer's and eczema [4] - Eli Lilly has a strong track record of dividend growth, having increased payouts by 200% over the past decade, although its forward yield is 0.7% [5] Group 2: Shopify - Shopify specializes in e-commerce, providing a comprehensive platform for small and medium-sized merchants to establish online stores and manage various business functions [6] - The company holds over 10% market share in the U.S. e-commerce space, with 2024 revenue reaching $8.9 billion, a 26% increase from the previous year, and a net income of $2 billion [7][8] - Shopify benefits from high switching costs for merchants, creating a competitive advantage, and has significant growth potential in the e-commerce sector, where online sales accounted for only 16.4% of total retail sales in Q4 [9][10] - The company's focus on long-term growth and increased profitability positions it as a strong investment opportunity [11]

Core Insights - Eli Lilly and Company announced preclinical data for agents targeting SMARCA2 and multiple KRAS mutations to be presented at the AACR Annual Meeting from April 25-30, 2025 [1] Group 1: Presentation Details - Lilly, in collaboration with Foghorn Therapeutics, will present preclinical data for LY4050784, a selective SMARCA2 inhibitor, in combination with chemotherapy, pembrolizumab, and KRAS inhibitors [2] - Preclinical data for LY4066434, a pan-KRAS inhibitor, will also be presented, demonstrating robust anti-tumor activity in KRAS-mutant models [2] - Specific presentation details include: - Title: LY4050784, a selective inhibitor of SMARCA2, demonstrates synergistic activity in combinations with pembrolizumab or KRAS inhibitors - Abstract Number: 3779 - Session Date & Time: April 28, 2:30-4:30 p.m. CST - Presenter: Nathan Brooks [2] - Title: LY4066434, an oral small molecule pan-KRAS inhibitor, demonstrates robust anti-tumor activity in KRAS-mutant models, including in the CNS - Abstract Number: 4375 - Session Date & Time: April 29, 9 a.m.-12 p.m. CST - Presenter: Hong Gao [2] Group 2: Company Overview - Eli Lilly is focused on turning scientific discoveries into healing solutions, with a history of nearly 150 years in pioneering life-changing medicines [3] - The company aims to address significant health challenges, including diabetes care, obesity, Alzheimer's disease, immune system disorders, and difficult-to-treat cancers [3] - Lilly emphasizes the importance of innovative clinical trials that reflect global diversity and aims to ensure accessibility and affordability of its medicines [3]